Cargando…

Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer

BACKGROUND: Bevacizumab has become standard of care as first-line treatment of metastatic colorectal cancer (mCRC), after proving increased response rates and improvement in survival outcomes. Hypertension (HTN) is a common complication of the treatment with bevacizumab and, owing to its close relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dionísio de Sousa, Isabel José, Ferreira, Joana, Rodrigues, Joana, Bonito, Nuno, Jacinto, Paula, Marques, Mariela, Ribeiro, João, Pais, Ana, Gervásio, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070256/ https://www.ncbi.nlm.nih.gov/pubmed/27843607 http://dx.doi.org/10.1136/esmoopen-2016-000045

Ejemplares similares

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer
por: Feliu, Jaime, et al.
Publicado: (2015)

Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis
por: Zhang, Chun-Jing, et al.
Publicado: (2018)

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
por: Cai, Jun, et al.
Publicado: (2013)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Oncofertility in pediatric patients: current perspectives
por: Marques, Rafael, et al.
Publicado: (2022)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2016)

Stress affects theta activity in limbic networks and impairs novelty-induced exploration and familiarization
por: Jacinto, Luis R., et al.
Publicado: (2013)

Age effects on EEG correlates of the Wisconsin Card Sorting Test
por: Dias, Nuno S, et al.
Publicado: (2015)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection
por: Osterlund, Pia, et al.
Publicado: (2014)

Blood–brain-barriers in aging and in Alzheimer’s disease
por: Marques, Fernanda, et al.
Publicado: (2013)

Use of Bevacizumab in Metastatic Colorectal Cancer: Report from the Mexican Opinion and Analysis Forum on Colorectal Cancer Treatment with Bevacizumab (September 2009)
por: Zinser-Sierra, Juan W., et al.
Publicado: (2012)

Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
por: Ghiringhelli, Francois, et al.
Publicado: (2014)

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer
por: Papachristos, Apostolos, et al.
Publicado: (2020)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
por: Dinu, Ioana Mihaela, et al.
Publicado: (2023)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
por: Kim, Seijong, et al.
Publicado: (2022)

Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
por: Paiva, Tadeu Ferreira, et al.
Publicado: (2015)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

Topographical Analysis of the Subependymal Zone Neurogenic Niche
por: Falcão, Ana Mendanha, et al.
Publicado: (2012)

Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases
por: Alcaide, Julia, et al.
Publicado: (2016)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
por: Razenberg, L. G. E. M., et al.
Publicado: (2016)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
por: Passardi, Alessandro, et al.
Publicado: (2016)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
por: You, Xia-Hong, et al.
Publicado: (2019)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Gastrointestinal Perforation With an Intraluminal Stent and Bevacizumab use in Advanced Metastatic Colorectal Cancer
por: Akeel, Nouf, et al.
Publicado: (2021)

Geometric compensation applied to image analysis of cell populations with morphological variability: a new role for a classical concept
por: Figueiredo, Joana, et al.
Publicado: (2018)

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
por: Jin, Ran, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gok7hlisktogbo9sst64o43nv3